TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02760615
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole capsules
Study: NCT02760615
Drug: Dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan capsules
Study: NCT02760615
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam syrup
Study: NCT02760615
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab solution for IV infusion
Study: NCT00669890
Drug: Gemtuzumab Ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose Escalation
Study: NCT00669890
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conditioning Regimen
Study: NCT00669890
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Unrelated Donors only)
Study: NCT00669890
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GVHD Prophylaxis
Study: NCT00669890
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GVHD Prophylaxis
Study: NCT02988778
Drug: Budesonid 50mcg (Noex)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
Study: NCT02988778
Drug: Budesonid 50mcg (Busonid)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
Study: NCT02587741
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: start with metformin，from 500mg bid,if metformin reach the biggest dosage，added gliclazide modified release tablets，afterthat，add acarbose
Study: NCT02587741
Drug: Lantus
Normalized name: Lantus
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: started with insulin glargine 0.2 u/kg subcutaneous injection ，add dosage if glucose dose not reach the target.after that,you can add oral drugs（like oral drug group）
Study: NCT03790566
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 ml/kg 0.25% bupivacaine
Study: NCT00830544
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab
Study: NCT00830544
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental chemotherapy regimen
Study: NCT00646139
Drug: Src kinase inhibitor KX2-391
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02699658
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02282930
Drug: ACTH (Acthar) Gel
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injected dose of 80 units subcutaneously twice weekly for 6 months.
Study: NCT01480661
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast 500 µg, once a day in the morning during 6 months
Study: NCT01480661
Drug: Placebo of Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo 500 µg, once a day in the morning during 6 months
Study: NCT00895531
Drug: Depodur
Normalized name: Depodur
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 mg Depodur via the epidural catheter
Study: NCT02650544
Drug: Mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in mirtazapine arm will be orally administered mirtazapine as an anti-depression therapy; along with palliative chemotherapy.
Study: NCT00057928
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00057928
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00057928
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00790946
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan 80 to 160 mg
Study: NCT01356160
Drug: GS-5885
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet, 30 mg QD
Study: NCT01356160
Drug: GS-9451
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet, 200 mg QD
Study: NCT01356160
Drug: ribavirin tablet
Normalized name: Ribavirin Tablets
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
Study: NCT01361555
Drug: Placebo matching with BMS-820836
Normalized name: BMS-820836
DrugBank: Liafensine (DB14878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, 0.0 mg, Once daily, 54 weeks
Study: NCT01361555
Drug: BMS-820836
Normalized name: BMS-820836
DrugBank: Liafensine (DB14878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, 0.5 mg, Once daily, 54 weeks
Study: NCT01361555
Drug: BMS-820836
Normalized name: BMS-820836
DrugBank: Liafensine (DB14878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, 1.0 mg, Once daily, 54 weeks
Study: NCT01361555
Drug: BMS-820836
Normalized name: BMS-820836
DrugBank: Liafensine (DB14878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, 2.0 mg, Once daily, 54 weeks
Study: NCT01486875
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose individually adjusted, and administered subcutaneously (under the skin) once or twice daily
Study: NCT03576508
Drug: Qutenza
Normalized name: Qutenza
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8% topical patch
Study: NCT03576508
Drug: Lidocaine (without epinephrine)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mL IA injection of 2% lidocaine (without epinephrine)
Study: NCT01855867
Drug: Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00701285
Drug: pitavastatin
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pitavastatin 4mg once daily
Study: NCT01476423
Drug: activated recombinant human factor VII
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A prospective, observational multi-national registry collecting data and evaluating the efficacy and safety of rFVIIa in patients with GT with past or present refractoriness to platelet transfusions. The registry will also collect data from a broader range of GT patients treated with systemic haemostatic treatment (with or without antifibrinolytic drugs or other agents) used in the clinics. Data collection will continue for a maximum of six years. Baseline data as well as data obtained during either bleeding episodes or invasive procedures/surgeries will be recorded in the registry.
Study: NCT02023424
Drug: Glatiramer Acetate (Copaxone®)
Normalized name: Glatiramer
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA is a potent inducer of Th2-cells and modulates these immune cells to secrete high levels of neurotrophic factors, particularly BDNF. The induced cells cross the blood brain barrier (BBB), accumulate in the CNS and express BDNF and other regulatory substances in situ.
Study: NCT01983046
Drug: Three different mixture of acetate, butyrate and propionate and palcebo
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03607149
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: standard arm : calculating the dose of pemetrexed according to body surface area~experimental arm: calculation of the dose of pemetrexed as a function of creatinine clearance (CrCLCG)
Study: NCT00786669
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles
Study: NCT00786669
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.
Study: NCT00786669
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients \<0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).
Study: NCT00786669
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles
Study: NCT01188369
Drug: levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation.
Study: NCT00786669
Drug: Cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity
Study: NCT01839526
Drug: Iohexol
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.
Study: NCT03473236
Drug: GB002
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inhaled GB002
Study: NCT03684044
Drug: Baloxavir Marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baloxavir marboxil will be administered as a weight-based dose on Days 1 and 4. A third dose will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.
Study: NCT00418496
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600,000 IU/kg every 8 hours on days 1-5 (week 1) to a maximum of 12 doses. Another cycle of HD aldesleukin will be started on day 15 (week 3).
Study: NCT00418496
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To be initiated at a dose of 200 mg orally. Once it is determined that no further HD aldesleukin therapy will be given, sorafenib may be given daily at the FDA approved dose of 400 mg twice daily until there is lack of clinical benefit or intolerable side effects develop.
Study: NCT02698813
Drug: hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03455504
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax add in combination with fludarabine, cyratabine and idarubicine
Study: NCT00353340
Drug: sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00353340
Drug: sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00394199
Drug: Fluticasone propionate/Formoterol Fumarate 100/10
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study: NCT00394199
Drug: Fluticasone propionate 100
Normalized name: FLUTICASONE PROPIONATE 100MCG INHL,ORAL,DISKUS,60
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone 100 is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study: NCT00394199
Drug: Formoterol fumarate 10
Normalized name: FORMOTEROL FUMARATE 10MCG/ML SOLN,INH,2ML
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study: NCT00828971
Drug: Avelox (Moxifloxacin, BAY12-8039)
Normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.
Study: NCT00828971
Drug: Amoxicilline/clavulanic
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days
Study: NCT03651128
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab
Study: NCT03651128
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide
Study: NCT03651128
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone
Study: NCT03651128
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib
Study: NCT03651128
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib
Study: NCT03651128
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide
Study: NCT03651128
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib
Study: NCT03651128
Drug: Elotuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elotuzumab
Study: NCT00487994
Drug: Lapaquistat acetate
Normalized name: Lapaquistat
DrugBank: Lapaquistat (DB16215)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
Study: NCT00487994
Drug: Lapaquistat acetate and atorvastatin
Normalized name: atorvastatin and amlodipine
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
Study: NCT00487994
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
Study: NCT04101227
Drug: AD04 (ondansetron)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AD04 (ondansetron) 0.33 mg, orally (p.o.) twice a day (BID)
Study: NCT00826540
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00255359
Drug: XTL-2125
Normalized name: XTL-001
DrugBank: XTL-001 (DB05405)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03427021
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusion
Study: NCT02316730
Drug: Sanchi-Tongshu Capsule (Enteric coated pellets)
Normalized name: budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Take 0.7g (2 Capsules) of test preparation orally.
Study: NCT02316730
Drug: Sanchi-Tongshu Capsule
Normalized name: Sanchi
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 0.4g (2 Capsules) of reference preparation orally.
Study: NCT00190606
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03381053
Drug: Imatinib 400mg
Normalized name: imatinib 400 MG
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The NIH assessment of patients with surgical excision of GIST with moderate to high risk of recurrence was recommended imatinib 400mg treatment.
Study: NCT03380390
Drug: Oxymetazoline HCL 1.0% Cream
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline HCl cream 1.0% once daily application
Study: NCT03588715
Drug: Pegylated Interferon alpha 2b (peg-IFN-α2b)
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegylated Interferon alpha 2b (peg-IFN-α2b) will be administered weekly via subcutaneous route.
Study: NCT03087578
Drug: Mirabegron 50 MG [Myrbetriq]
Normalized name: mirabegron 50 MG [Myrbetriq]
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 50 mg of mirabegron daily for 6 weeks.
Study: NCT00877890
Drug: exenatide once weekly
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection, 2.0mg, once a week
Study: NCT00877890
Drug: exenatide twice daily
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
Study: NCT03071263
Drug: Patiromer
Normalized name: Patiromer
DrugBank: Patiromer (DB09263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 packets/day starting dose, administered orally
Study: NCT01681836
Drug: 15Nitrogen(15N)-labeled sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrogen (DB09152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15Nitrogen(15N)-labeled sodium nitrite 20 mg once
Study: NCT01681836
Drug: 15Nitrogen(15N)-labeled sodium nitrate
Normalized name: sodium nitrate 15N
DrugBank: Nitrogen (DB09152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15Nitrogen(15N)-labeled sodium nitrate 1,000 mg once
Study: NCT01731756
Drug: Salicylic Acid (6%)
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
Study: NCT01308528
Drug: Sodium enoxaparin
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/mL
Study: NCT00510887
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib 1.6 mg/m2 on days 1 and 8 of each 28-day cycle
Study: NCT00510887
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 IV on day 1
Study: NCT00510887
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 25 mg/m2 IV on days 1,2,3
Study: NCT00510887
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone 10 mg/m2 IV on day 2
Study: NCT01308528
Drug: Sodium Enoxaparin clexane
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clexane 40 mg/ 0,4 mL
Study: NCT00510887
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 20 mg orally on days 1,2,3,4,5
Study: NCT00466063
Drug: Deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04211740
Drug: OCH-NCNP1
Normalized name: NS 089/NCNP 02
DrugBank: Brogidirsen (DB18884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCH-NCNP1 3mg is supplied as granules and take orally once a week.
Study: NCT02735044
Drug: Insulin glargine,300 U/mL
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 milligram/deciliter (mg/dL) (5.0 to 7.2 millimol per liter \[mmol/L\])
Study: NCT02735044
Drug: Insulin glargine (100 units /mL)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L)
Study: NCT00864123
Drug: D-cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (Seromycin, 250 mg; Eli Lilly and Co, Indianapolis, Indiana) will be capsulated into 25mg with identical placebo capsules. Children weighing between 25-45kg will be given a dosage of 25mg (approximately 0.56-1.0 mg/kg/day). Children weighing between 46-80kg will be given a dosage of 50mg (approximately 0.63-1.08mg/kg/day). DCS or placebo will be given by parents 1 hour prior to psychotherapy sessions (before sessions 4-10 only) based on past success in patients with acrophobia (Ressler et al., 2004) and DCS absorption rates.